<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Gentamicin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00798</strong>&#160; (APRD00214)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A complex of three different closely related aminoglycoside sulfates, Gentamicins C1, C2, and C1a, obtained from Micromonospora purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit protein synthesis (genetic translation). [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00798/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00798/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00798.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00798.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00798.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00798.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00798.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00798">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Gentamicin Sulfate</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000690/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000690/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: CEAZRRDELHUEMR-UHFFFAOYNA-N</li>
              <li>Monoisotopic Mass: 477.316248755</li>
              <li>Average Mass: 477.5954</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000690">DBSALT000690</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Alcomicin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Bristagen</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>G-Mycin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Garamycin</td><td>Schering-Plough</td></tr><tr><td>Genoptic</td><td>Allergan</td></tr><tr><td>Gentacidin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Gentafair</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Gentak</td><td>Akorn</td></tr><tr><td>Gentamar</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Jenamicin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ocu-Mycin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Spectro-Genta</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>U-gencin</td><td>U-Liang</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Diprogen Cream</td><td>Betamethasone Dipropionate + Gentamicin Sulfate</td></tr><tr><td>Diprogen Ont</td><td>Betamethasone Dipropionate + Gentamicin Sulfate</td></tr><tr><td>Garasone Oph/Ot Sol</td><td>Betamethasone + Gentamicin Sulfate</td></tr><tr><td>Garasone Ophthalmic Ointment</td><td>Betamethasone + Gentamicin Sulfate</td></tr><tr><td>Gentamicin Sulfate in Nacl 0.9% Inj</td><td>Gentamicin Sulfate + Sodium Chloride</td></tr><tr><td>Gentocin Durafilm</td><td>Betamethasone 21-Acetate + Gentamicin Sulfate</td></tr><tr><td>Gentocin Otic Solution</td><td>Betamethasone + Gentamicin Sulfate</td></tr><tr><td>Otomax Ointment</td><td>Betamethasone + Clotrimazole + Gentamicin Sulfate</td></tr><tr><td>PRED-G</td><td>Gentamicin + Prednisolone</td></tr><tr><td>Sandoz Pentasone</td><td>Betamethasone + Gentamicin Sulfate</td></tr><tr><td>Topagen Ont</td><td>Betamethasone + Gentamicin Sulfate</td></tr><tr><td>Topagen Spray</td><td>Betamethasone + Gentamicin Sulfate</td></tr><tr><td>Valisone G Cream</td><td>Betamethasone + Gentamicin Sulfate</td></tr><tr><td>Valisone G Ointment</td><td>Betamethasone + Gentamicin Sulfate</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/aminoglycosides">Aminoglycosides</a></li></ul></td></tr><tr><th>CAS number</th><td>1403-66-3</td></tr><tr><th>Weight</th><td>Average: 477.5954<br>Monoisotopic: 477.316248755</td></tr><tr><th>Chemical Formula</th><td>C<sub>21</sub>H<sub>43</sub>N<sub>5</sub>O<sub>7</sub></td></tr><tr><th>InChI Key</th><td>CEAZRRDELHUEMR-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C21H43N5O7/c1-9(25-3)13-6-5-10(22)19(31-13)32-16-11(23)7-12(24)17(14(16)27)33-20-15(28)18(26-4)21(2,29)8-30-20/h9-20,25-29H,5-8,22-24H2,1-4H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-{[4,6-diamino-3-({3-amino-6-[1-(methylamino)ethyl]oxan-2-yl}oxy)-2-hydroxycyclohexyl]oxy}-5-methyl-4-(methylamino)oxane-3,5-diol</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organooxygen Compounds</td></tr><tr><th>Class</th><td>Carbohydrates and Carbohydrate Conjugates</td></tr><tr><th>Subclass</th><td>Amino Sugars</td></tr><tr><th>Direct parent</th><td>Aminocyclitol Glycosides</td></tr><tr><th>Alternative parents</th><td>Dihexoses; O-glycosyl Compounds; Aminocyclitols and Derivatives; Cyclohexanols; Oxanes; Tertiary Alcohols; 1,2-Aminoalcohols; Polyamines; Dialkylamines; Acetals; Monoalkylamines</td></tr><tr><th>Substituents</th><td>o-glycosyl compound; glycosyl compound; disaccharide; aminocyclitol derivative; cyclitol derivative; cyclohexanol; oxane; tertiary alcohol; cyclic alcohol; 1,2-aminoalcohol; secondary alcohol; secondary aliphatic amine; polyamine; acetal; secondary amine; ether; alcohol; amine; organonitrogen compound; primary aliphatic amine; primary amine</td></tr><tr><th>Classification description</th><td>This compound belongs to the aminocyclitol glycosides. These are organic compounds containing an amicocyclitol moiety glycosidially linked to a carbohydrate moiety.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For treatment of serious infections caused by susceptible strains of the following microorganisms: <i>P. aeruginosa</i>, <i>Proteus</i> species (indole-positive and indole-negative), <i>E. coli</i>, <i>Klebsiella-Enterobactor-Serratia</i> species, <i>Citrobacter</i> species and <i>Staphylococcus</i> species (coagulase-positive and coagulase-negative).</td></tr><tr><th>Pharmacodynamics</th><td>Gentamicin is a broad spectrum aminoglycoside antibiotic. Aminoglycosides work by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA, leaving the bacterium unable to synthesize proteins vital to its growth. Aminoglycosides are useful primarily in infections involving aerobic, Gram-negative bacteria, such as Pseudomonas, Acinetobacter, and Enterobacter. In addition, some mycobacteria, including the bacteria that cause tuberculosis, are susceptible to aminoglycosides. Infections caused by Gram-positive bacteria can also be treated with aminoglycosides, but other types of antibiotics are more potent and less damaging to the host. In the past the aminoglycosides have been used in conjunction with penicillin-related antibiotics in streptococcal infections for their synergistic effects, particularly in endocarditis. Aminoglycosides are mostly ineffective against anaerobic bacteria, fungi and viruses.</td></tr><tr><th>Mechanism of action</th><td>Aminoglycosides like gentamicin "irreversibly" bind to specific 30S-subunit proteins and 16S rRNA. Specifically gentamicin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes.</td></tr><tr><th>Absorption</th><td>Injections lead to peak serum concentrations in 30-60 minutes. Topical gentamicin is readily absorbed from large burned, denuded, or granulating areas but not through intact skin. Absorption of gentamicin is faster and greater with the cream compared to the ointment. Gentamicin is absorbed in small quantities following topical application to the eye. Gentamicin is also absorbed in small amounts following topical application to the ear (especially if the eardrum is perforated or if tissue damage is present). Gentamicin is very poorly absorbed orally. </td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>Low (between 0 and 30%)</td></tr><tr><th>Metabolism</th><td class="data-table-container"></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>3-3&#189; hours in infants one week to six months of age; this increases to 5&#189; hours in full-term and large premature infants less than one week old.</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Mild and reversible nephrotoxicity may be observed in 5 - 25% of patients. Gentamicin accumulates in proximal renal tubular cells and causes cell damage. Tubular cell regeneration occurs despite continued drug exposure. Toxicity usually occurs several days following initiation of therapy. May cause irreversible ototoxicity. Otoxocity appears to be correlated to cumulative lifetime exposure. Drug accumulation in the endolymph and perilymph of the inner ear causes irreversible damage to hair cells of the cochlea or summit of ampullar cristae in the vestibular complex. High frequency hearing is lost first with progression leading to loss of low frequency hearing. Further toxicity may lead to retrograde degeneration of the 8th cranial (vestibulocochlear) nerve. Vestibular toxicity may cause vertigo, nausea, vomiting, dizziness and loss of balance.
Mouse, intravenous LD50: 52 mg/kg; rat, intravenous LD50: 96 mg/kg.</td></tr><tr><th>Affected organisms</th><td><ul><li>Enteric bacteria and other eubacteria</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Gentamicin Action Pathway</td><td>Drug action</td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              -
        </td>
        <td>0.944</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.9826</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.6987</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.6882</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6808</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9586</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8738</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8001</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8314</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.5917</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9034</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.891</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9331</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9043</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9517</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9294</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.7338
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9696
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9588
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.0383 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9954
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8784
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Schering corp sub schering plough corp</li>
<li>Pharmafair inc</li>
<li>Alpharma us pharmaceuticals division</li>
<li>Bausch and lomb pharmaceuticals inc</li>
<li>E fougera div altana inc</li>
<li>Perrigo new york inc</li>
<li>Pharmaderm div altana inc</li>
<li>Taro pharmaceuticals usa inc</li>
<li>King pharmaceuticals inc</li>
<li>Bristol laboratories inc div bristol myers co</li>
<li>International medication systems ltd</li>
<li>Abbott laboratories pharmaceutical products div</li>
<li>App pharmaceuticals llc</li>
<li>Baxter healthcare corp anesthesia and critical care</li>
<li>Hospira inc</li>
<li>Kalapharm inc</li>
<li>Pharmaceutical specialist assoc</li>
<li>Solopak laboratories inc</li>
<li>Teva parenteral medicines inc</li>
<li>Watson laboratories inc</li>
<li>Wyeth ayerst laboratories</li>
<li>B braun medical inc</li>
<li>Baxter healthcare corp</li>
<li>Pharmacia and upjohn co</li>
<li>Novartis pharmaceuticals corp</li>
<li>Akorn inc</li>
<li>Altana inc</li>
<li>Allergan</li>
<li>Alcon universal ltd</li>
<li>Falcon pharmaceuticals ltd</li>
<li>Paco research corp</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.accutome.com">Accutome Inc.</a></li>
<li>Advanced Pharmaceutical Services Inc.</li>
<li><a href="http://www.akorn.com">Akorn Inc.</a></li>
<li><a href="http://www.alcon.com">Alcon Laboratories</a></li>
<li><a href="http://www.apppharma.com">APP Pharmaceuticals</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.bbraun.com">B. Braun Melsungen AG</a></li>
<li><a href="http://www.bausch.com">Bausch &amp; Lomb Inc.</a></li>
<li><a href="http://www.baxter.com">Baxter International Inc.</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li>Carlisle Laboratories Inc.</li>
<li><a href="http://www.darbydental.com">Darby Dental Supply Co. Inc.</a></li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.fougera.com">E. Fougera and Co.</a></li>
<li><a href="http://www.falconpharma.com">Falcon Pharmaceuticals Ltd.</a></li>
<li><a href="http://www.giv.com">General Injectables and Vaccines Inc.</a></li>
<li><a href="http://hjharkinscompanyinc.com">H.J. Harkins Co. Inc.</a></li>
<li><a href="http://www.hospira.com">Hospira Inc.</a></li>
<li><a href="http://www.innoviantpharmacy.com">Innoviant Pharmacy Inc.</a></li>
<li><a href="http://www.keltman.com">Keltman Pharmaceuticals Inc.</a></li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li>Martin Surgical Supply</li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li><a href="http://www.mwivet.com">MWI Veterinary Supply Co.</a></li>
<li><a href="http://www.novartis.com">Novartis AG</a></li>
<li><a href="http://www.nycomed.com">Nycomed Inc.</a></li>
<li><a href="http://www.ocusoft.com">Ocusoft</a></li>
<li>OMJ Pharmaceuticals</li>
<li>Pacific Pharma Lp</li>
<li><a href="http://www.palmettopharm.com">Palmetto Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.perrigo.com">Perrigo Co.</a></li>
<li><a href="http://www.pharmedixrx.com">Pharmedix</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.preferredpharmaceuticals.com">Preferred Pharmaceuticals Inc.</a></li>
<li><a href="http://www.worldoftest.com">Qualitest</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li>Redpharm Drug</li>
<li>Rx Veterinary Products</li>
<li><a href="http://statrxusa.exporterus.com">Stat Rx Usa</a></li>
<li><a href="http://www.stat-scripts.com">Stat Scripts LLC</a></li>
<li><a href="http://www.tarousa.com">Taro Pharmaceuticals USA</a></li>
<li>Taylor Pharmaceuticals</li>
<li><a href="http://www.vedco.com">Vedco Inc.</a></li>
<li>Wa Butler Co.</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Cream</td><td>Topical</td><td></td></tr><tr><td>Liquid</td><td>Ophthalmic</td><td></td></tr><tr><td>Ointment</td><td>Ophthalmic</td><td></td></tr><tr><td>Ointment</td><td>Topical</td><td></td></tr><tr><td>Solution</td><td>Auricular (otic)</td><td></td></tr><tr><td>Solution</td><td>Intravenous</td><td></td></tr><tr><td>Solution</td><td>Ophthalmic</td><td></td></tr><tr><td>Solution / drops</td><td>Auricular (otic)</td><td></td></tr><tr><td>Solution / drops</td><td>Ophthalmic</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00732">Atracurium</a></td><td>The agent increases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB00887">Bumetanide</a></td><td>Increased ototoxicity</td></tr><tr><td><a href="/drugs/DB01326">Cefamandole</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01139">Cefapirin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01327">Cefazolin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01328">Cefonicid</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01329">Cefoperazone</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00923">Ceforanide</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00493">Cefotaxime</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01330">Cefotetan</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01331">Cefoxitin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01333">Cefradine</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00438">Ceftazidime</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01332">Ceftizoxime</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01212">Ceftriaxone</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01112">Cefuroxime</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB03450">Cephalothin Group</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00515">Cisplatin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01111">Colistimethate</a></td><td>Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. Due to the potential for additive or synergistic toxicities (including both nephrotoxicity and neuromuscular blockade) between colistimethate and the aminoglycoside antibiotics, this combination should be avoided whenever possible. If these agents must be used together, patients' renal and neuromuscular function should be monitored closely. </td></tr><tr><td><a href="/drugs/DB01135">Doxacurium chloride</a></td><td>The agent increases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB00903">Ethacrynic acid</a></td><td>Increased ototoxicity</td></tr><tr><td><a href="/drugs/DB00695">Furosemide</a></td><td>Increased ototoxicity</td></tr><tr><td><a href="/drugs/DB01336">Metocurine</a></td><td>The agent increases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB01226">Mivacurium</a></td><td>The agent increases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB01337">Pancuronium</a></td><td>The agent increases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB01338">Pipecuronium</a></td><td>The agent increases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB00728">Rocuronium</a></td><td>The agent increases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB00202">Succinylcholine</a></td><td>The agent increases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Gentamicin. Use caution during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB01041">Thalidomide</a></td><td>Thalidomide increases the renal toxicity of the aminoglycoside</td></tr><tr><td><a href="/drugs/DB01607">Ticarcillin</a></td><td>Ticarcillin may reduce the serum concentration of Gentamicin. Ticarcillin may inactivate Gentamicin in vitro and the two agents should not be administered simultaneously through the same IV line.</td></tr><tr><td><a href="/drugs/DB00214">Torasemide</a></td><td>Increased ototoxicity</td></tr><tr><td><a href="/drugs/DB01199">Tubocurarine</a></td><td>The agent increases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB01339">Vecuronium</a></td><td>The agent increases the effect of muscle relaxant</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>